Publicação
The role of biotics as a therapeutic strategy for oral mucositis - a systematic review
| dc.contributor.author | Frey-Furtado, Leonor | |
| dc.contributor.author | Magalhães, Inês | |
| dc.contributor.author | Azevedo, Maria João | |
| dc.contributor.author | Sampaio-Maia, Benedita | |
| dc.date.accessioned | 2023-07-26T16:32:55Z | |
| dc.date.available | 2023-07-26T16:32:55Z | |
| dc.date.issued | 2024-08-01 | |
| dc.description.abstract | Objectives: Oral mucositis (OM) is an acute and highly prevalent side effect of cancer treatments. Currently, there is no effective strategy for its prevention or treatment. This systematic review aimed to assess the effectiveness of biotics used as a therapeutic strategy for the management of OM. Materials and Methods: The PRISMA checklist was followed and PubMed, Web of Science, and Scopus were screened for clinical and pre-clinical studies assessing the potential effects of biotics in OM. Inclusion criteria included in vivo studies related to oral mucositis evaluating the effect of biotics, and written in Portuguese, English, French, Spanish, or Dutch. The following exclusion criteria were used: systematic reviews and meta-analyses, reviews, case reports, opinion papers or comments, conference papers, letters without results, articles not related to oral therapy-induced mucositis or biotics, or in vitro articles that do not simulate oral mucositis. Results: From a total of 1250 articles retrieved, 9 were included in this systematic review. Four clinical studies reported a reduction in oral mucositis occurrence with Lactobacillus species (Lactobacillus casei and Lactobacillus brevis CD2) and Bacillus clausii UBBC07. In pre-clinical studies, Lactococcus lactis genetically modified and Lactobacillus reuteri reduced the severity of OM and Streptococcus salivarius K12 also decreased the size of the ulcers. Conclusion: The findings of this systematic review suggest that probiotic supplementation may potentially reduce the incidence of therapy-induced OM and decrease its severity in patients undergoing cancer treatment. However, the available evidence is marred by significant heterogeneity across studies. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.doi | 10.1007/s12602-023-10116-z | pt_PT |
| dc.identifier.eid | 85163744099 | |
| dc.identifier.issn | 1867-1306 | |
| dc.identifier.pmid | 37389790 | |
| dc.identifier.uri | http://hdl.handle.net/10400.14/41943 | |
| dc.identifier.wos | 001020407900002 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.subject | Head and neck cancer | pt_PT |
| dc.subject | Oral cancer | pt_PT |
| dc.subject | Oral mucositis | pt_PT |
| dc.subject | Prebiotics | pt_PT |
| dc.subject | Probiotics | pt_PT |
| dc.title | The role of biotics as a therapeutic strategy for oral mucositis - a systematic review | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 1326 | |
| oaire.citation.issue | 4 | |
| oaire.citation.startPage | 1313 | |
| oaire.citation.title | Probiotics and Antimicrobial Proteins | pt_PT |
| oaire.citation.volume | 16 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |